LONDON, Sept. 9, 2019 /PRNewswire/ -- On
7th September 2019, the
USA's Food & Drug
Administration issued a statement in response to recent reports of
respiratory illnesses following the use of vaping products. This
statement included a recommendation that consumers should "avoid
buying vaping products of any kind on the street, and to refrain
from using THC oil or modifying/adding any substances to products
purchased in stores". Below is British American Tobacco response to
this statement.
Dr David O'Reilly, Director of
Scientific Research, British American Tobacco, said:
"As one of the world's largest vapour companies, providing
high quality products to more than 9 million consumers, we take our
consumer safety responsibilities very seriously. We apply industry
leading standards of quality and safety testing to the way we
develop and manufacture our products all around the world.
"Every single ingredient and component in these products has
been scrutinised by our toxicologists for their suitability for
vaping. Consistent with this, oils containing THC and Vitamin E
Acetate are not, and have never been, added to our vaping
products.
"From the USA Food and Drug
Administration's (FDA) statements we have seen, these tragic events
appear to be a new phenomenon linked to liquids that were not
sourced from reputable manufacturers and which contained
ingredients, including THC and Vitamin E Acetate, which we do not
use.
"These cases highlight the importance of effective regulation
and enforcement to ensure product safety.
"We fully support the FDA's view that vapers should always
source their devices and liquids from reputable manufacturers,
should avoid modifying or adding substances to the products they
purchase and should only ever use the devices as the manufacturer
intended.
"We are monitoring the situation in the USA and will work closely with all relevant
Public Health Authorities around the world such as the FDA, the
Centre for Disease Control and Prevention and Public Health
England."
Forward looking statements
This is a release by British American Tobacco p.l.c. Associate
companies are excluded. References to 'British American Tobacco',
'BAT', 'we', 'us' and 'our' when denoting opinion refer to British
American Tobacco p.l.c. (the Company, and together with its
subsidiaries, the "Group"), and when denoting tobacco business
activity refer to Group operating companies, collectively or
individually as the case may be. This release contains certain
forward-looking statements, made within the meaning of Section 21E
of the United States Securities Exchange Act of 1934, regarding our
intentions, beliefs or current expectations reflecting knowledge
and information available at the time of preparation and
concerning, amongst other things, prospects, growth and strategies.
BAT undertakes no obligation to update or revise these
forward-looking statements, whether as a result of new information,
future events or otherwise.
These statements are often, but not always, made through the use of
words or phrases such as "believe," "anticipate," "could," "may,"
"would," "should," "intend," "plan," "potential," "predict,"
"will," "estimate," "strategy" and similar expressions. It is
believed that the expectations reflected in this release are
reasonable but they may be affected by a wide range of variables
that could cause actual results to differ materially from those
currently anticipated.
Logo:
https://mma.prnewswire.com/media/785820/British_American_Tobacco_Logo.jpg